Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G

AEON Biopharma, Inc.

AEONNYSE_AMERICANEQUITYCurrent

Beneficial Ownership Report

Filed Nov 13, 2026Accepted Nov 13, 2026, 4:52 PM ESTFiling CIK 1837607Accession 0001104659-26-127174
Share

Structured filing — SCHEDULE 13G

primary_doc.xml

Open full document ↗

Subject company

Company
AEON Biopharma, Inc.
Company CIK
0001837607
Street
130 VANTIS DRIVE
Street (continued)
SUITE 170
City
ALISO VIEJO
State / country code
CA
Postal code
92656

Statement details

Security class
Class A common stock, $0.0001 par value per share
Event date
09/30/2026
Rule designation
Rule 13d-1(b)

Reporting person 1

Name
Nantahala Capital Management, LLC
Citizenship / organization
MA
Reporting person type
IA
Aggregate amount owned
5,048,027.00
Percent of class
9.99
Sole voting power
0.00
Shared voting power
5,048,027.00
Sole dispositive power
0.00
Shared dispositive power
5,048,027.00
Aggregate excludes certain shares
N

Reporting person 2

Name
Wilmot B. Harkey
Citizenship / organization
X1
Reporting person type
HC
Aggregate amount owned
5,048,027.00
Percent of class
9.99
Sole voting power
0.00
Shared voting power
5,048,027.00
Sole dispositive power
0.00
Shared dispositive power
5,048,027.00
Aggregate excludes certain shares
N

Reporting person 3

Name
Daniel Mack
Citizenship / organization
X1
Reporting person type
HC
Aggregate amount owned
5,048,027.00
Percent of class
9.99
Sole voting power
0.00
Shared voting power
5,048,027.00
Sole dispositive power
0.00
Shared dispositive power
5,048,027.00
Aggregate excludes certain shares
N

Item 1

Issuer

AEON Biopharma, Inc.

Principal executive office address

130 VANTIS DRIVE SUITE 170 ALISO VIEJO, CALIFORNIA, 92656

Item 2

Citizenship

(1) Nantahala is a Massachusetts limited liability company. (2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.

Filing person

(1) Nantahala Capital Management, LLC ("Nantahala") (2) Wilmot B. Harkey (3) Daniel Mack (together the "Reporting Persons")

Principal business or residence address

130 Main St. 2nd Floor, New Canaan, Connecticut 06840

Item 3

Not applicable indication

N

Type of filing person

IA · HC

Item 4

Percent of class

As of September 30, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding: (1) Nantahala Capital Management, LLC ("Nantahala") : 9.99% (2) Wilmot B. Harkey: 9.99% (3) Daniel Mack: 9.99%

Amount beneficially owned

As of September 30, 2026, Nantahala may be deemed to be the beneficial owner of 5,048,027 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares. The 5048027 Shares Include 648027 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of convertible securities.

Sole voting power

(1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

Shared voting power

(1) Nantahala Capital Management, LLC ("Nantahala") : 5,048,027 Shares. (2) Wilmot B. Harkey: 5,048,027 Shares. (3) Daniel Mack: 5,048,027 Shares.

Sole dispositive power

(1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

Shared dispositive power

(1) Nantahala Capital Management, LLC ("Nantahala") : 5,048,027 Shares. (2) Wilmot B. Harkey: 5,048,027 Shares. (3) Daniel Mack: 5,048,027 Shares.

Item 5

Not applicable indication

Y

Item 6

Not applicable indication

N

Ownership on behalf of another person

BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of more than five percent of the outstanding shares of common stock beneficially owned by Nantahala reported herein.

Item 7

Not applicable indication

N

Subsidiaries

Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E). See Item 4(a).

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Exhibits

Exhibit 24 - Power of Attorney incorporated by reference to the November 13, 2026 filing. https://www.sec.gov/Archives/edgar/data/1502725/000110465926127115/0001104659-26-127115-index.htm.

Signature 1

Reporting person
Nantahala Capital Management, LLC
Signed
/s/ Taki Vasilakis
Title
Taki Vasilakis / Chief Compliance Officer
Date
11/13/2026

Signature 2

Reporting person
Wilmot B. Harkey
Signed
/s/ Taki Vasilakis, attorney-in-fact for
Title
Wilmot B. Harkey
Date
11/13/2026

Signature 3

Reporting person
Daniel Mack
Signed
/s/ Taki Vasilakis, attorney-in-fact for
Title
Daniel Mack
Date
11/13/2026

Company context

AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and the European Medicines Agency for the manufacture of certain third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.

Current securities

Historical securities (4)

Recent company filings

  1. 424B3 filingNov 3, 2026
  2. 8-K filingNov 3, 2026
  3. DEF 14A filingOct 26, 2026
  4. Regulation FD DisclosureOct 23, 2026
  5. PRE 14A filingOct 13, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.